Stockscreener 앱 받기
28.83
1.16%
0.2866
전일 마감가:
$28.54
열려 있는:
$28.1168
하루 거래량:
541.26K
Relative Volume:
0.65
시가총액:
$1.66B
수익:
$825.94M
순이익/손실:
$185.68M
주가수익비율:
9.0781
EPS:
3.1754
순현금흐름:
$296.89M
1주 성능:
+7.44%
1개월 성능:
-23.71%
6개월 성능:
-22.18%
1년 성능:
-14.71%
1일 변동 폭
$27.66
$28.95
1주일 범위
$25.90
$29.36
52주 변동 폭
$25.52
$40.87
하모니 바이오 Stock (HRMY) Company Profile
명칭
Harmony Biosciences Holdings Inc
전화
(484) 539-9800
주소
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
28.84 | 1.64B | 825.94M | 185.68M | 296.89M | 3.1754 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.73 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.45 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
764.24 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.21 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
313.29 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
하모니 바이오 Stock (HRMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-11 | 재개 | UBS | Neutral |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-17 | 개시 | H.C. Wainwright | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-10 | 개시 | UBS | Buy |
| 2024-06-21 | 개시 | Citigroup | Buy |
| 2024-01-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-09-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-20 | 개시 | BofA Securities | Neutral |
| 2022-10-14 | 업그레이드 | Janney | Neutral → Buy |
| 2022-10-14 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-04 | 개시 | Raymond James | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-03-29 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-14 | 개시 | Goldman | Neutral |
| 2020-09-14 | 개시 | Jefferies | Buy |
| 2020-09-14 | 개시 | Piper Sandler | Overweight |
모두보기
하모니 바이오 주식(HRMY)의 최신 뉴스
US applications for jobless aid rose modestly to 212,000 last week as layoffs remain at historically healthy levels - Bitget
Safe Bulkers, Inc. to Participate in the Dry Bulk Shipping Panel at the DNB Carnegie Energy & Shipping Conference in Oslo - Bitget
Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments - Yahoo! Finance Canada
Harmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval - simplywall.st
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
UBS Group Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $36.00 - MarketBeat
Harmony Biosciences (HRMY): UBS Lowers Price Target to $36 | HRM - GuruFocus
HC Wainwright Reiterates Buy Rating for HRMY with $55 Target | H - GuruFocus
Harmony Biosciences' (HRMY) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y - Finviz
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - Finviz
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry - Investing.com
Harmony Biosciences Holdings, Inc. Experiences Revision in Its Stock Evaluation Amid Market Volatility - Markets Mojo
Bank of America Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $28.00 - MarketBeat
Needham & Company LLC Issues Pessimistic Forecast for Harmony Biosciences (NASDAQ:HRMY) Stock Price - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2025 Earnings Call Transcript - Insider Monkey
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $36 at UBS - StreetInsider
CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
B of A Securities Lowers Harmony Biosciences (HRMY) Price Target to $28 | HRMY Stock News - GuruFocus
Decoding Harmony Biosciences Holdings Inc (HRMY): A Strategic SWOT Insight - GuruFocus
Harmony Biosciences Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Harmony Biosciences Holdings Inc (HRMY) Q4 2025 Earnings Call Hi - GuruFocus
Harmony Biosciences (HRMY) Reports Strong Q4 2025 Results, Eyes Blockbuster Revenue - GuruFocus
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $28 at BofA Securities - StreetInsider
Truist reiterates Hold on Harmony Biosciences stock, sets $25 target By Investing.com - Investing.com Canada
Truist reiterates Hold on Harmony Biosciences stock, sets $25 target - Investing.com UK
Truist SecuritiesReinstates $25 target on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Biosciences Holdings (HRMY) Stock Analysis: Positioned for a 70% Upside in Biotech Sector - DirectorsTalk Interviews
Harmony Biosciences Hits Day Low at $26.03 Amid Price Pressure - Markets Mojo
Harmony Biosciences Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Harmony Biosciences Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Harmony Bio misses Q4 2025 EPS estimates - Investing.com UK
Earnings call transcript: Harmony Bio misses Q4 2025 EPS estimates By Investing.com - Investing.com India
Zacks.com highlights 4 value stocks amid AI-driven market volatility - National Today
HRMY: Record revenue, strong WAKIX growth, and pipeline advances set up blockbuster 2026 - TradingView
Harmony Biosciences Holdings, Inc Reveals Retreat In Q4 Profit - Nasdaq
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates - Yahoo Finance
Harmony Biosciences Q4 Adjusted Net Income Drops, Net Product Revenue Rises; Full-Year 2026 Wakix Revenue Guidance Reiterated - marketscreener.com
Harmony Biosciences Reports $868.5 Million Revenue for 2025, Guidance for 2026 Exceeds $1 Billion - Intellectia AI
Harmony Biosciences Holdings, Inc. SEC 10-K Report - TradingView
Harmony Biosciences misses Q4 earnings despite revenue beat By Investing.com - Investing.com India
Harmony Biosciences misses Q4 earnings despite revenue beat - Investing.com
Earnings Flash (HRMY) Harmony Biosciences Holdings, Inc. Reports Q4 Revenue $243.8M, vs. FactSet Est of $240.3M - marketscreener.com
Harmony Biosciences Hldgs Earnings Review: Q4 Summary - Benzinga
Narcolepsy drug WAKIX nears $1B blockbuster year for Harmony Biosciences - Stock Titan
How The Story On Harmony Biosciences (HRMY) Is Shifting With Wakix Legal And Generic Risks - Yahoo Finance
Harmony Biosciences Shares Fall After Deutsche Bank Downgrade - marketscreener.com
Harmony Biosciences (HRMY) Faces Downgrades Amid Legal Concerns - GuruFocus
하모니 바이오 (HRMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
1.10%
자본화:
|
볼륨(24시간):